Navigation Links
Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
Date:3/16/2009

Net operating expenses decreased by 33% in 2008; Forecast cutting net operating expenses by approximately 50% in 2009

CTI expects to complete pixantrone NDA submission in Q2 2009

SEATTLE, March 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2008.

Recent Events

  • Met primary endpoint in the Phase III study of pixantrone in relapsed, aggressive non-Hodgkin's lymphoma with patients treated with pixantrone achieving a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). Additionally, demonstrated an increase in progression free survival of 81% compared to standard chemotherapeutic agents. CTI expects to complete submission of the pixantrone NDA in the second quarter of 2009. CTI will request priority review for the application. Potential approval by end of 2009.
  • Zevalin sales prior to the establishment of the joint venture with Spectrum Pharmaceuticals, Inc. (Spectrum) were approximately $11.4 million in 2008.
  • Sold an initial 50% interest in Zevalin to a 50/50 owned joint venture with Spectrum for $15 million in December 2008 and sold the remaining 50% interest in the Zevalin joint venture to Spectrum for approximately $16.5 million in March 2009, bringing total gross funds that will be received from Spectrum for 100% interest in Zevalin to $31.5 million. The transaction closed with CTI receiving $6.5 million on March 2, 2009, with the remaining $10 million to be received as follows: $6.5 million on April 3, 2009, and $3.5 million, subject to adjustments for expenses and revenues, on April 15, 2009. Zevalin was originally purchased
    '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
2. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
3. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
4. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
5. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
6. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
8. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
9. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
10. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
11. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... solid ... earnings growth., ST. DAVID,S, Bermuda, May 9 ... the quarter ended,March 31, 2008. Revenue in the quarter ended March 31, ... The primary,drivers of the increase in revenue were the net sales of ...
... May 9 Dr. Michael W. Long recently,was ... of the Year.,The "Leader & Innovator" award recognizes ... Michigan who have demonstrated or created unique,ideas, products ... life in our,communities. Nominees were recognized this month ...
... Northwest,Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC Bulletin ... Rajhi") has entered into an,agreement, executed on May 6 ... of US$4.0 million (the "Loan")., Under the terms ... for an unsecured promissory note in the principal amount ...
Cached Biology Technology:Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 3Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 4Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 5Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 6Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 7Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 8Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 9Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 10Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 11Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 12Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 13Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 14Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 15Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 16Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 17President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year 2President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year 3Northwest Secures US$4.0 Million in Debt Financing 2Northwest Secures US$4.0 Million in Debt Financing 3
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 The Defense ... easier to detect and prevent counterfeit microcircuits from entering ... started performing an in-house microcircuit anti-counterfeit initiative dubbed DNA ... microcircuits while increasing their reliability throughout the supply chain. ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced ... 2015-2019" report to their offering. ... a technology used for the identification of individuals. Facial ... person such as nose, jaw edges, mouth, and the ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... The Encyclopedia of Life (EOL, www.eol.org ) continues to ... content and partners. At the start of 2012, EOL provides ... content in Spanish, rich information about conservation issues from the ... and more images and videos than ever before. ...
... Protein May Be Not After All A bacterial protein ... not be after all. Researchers from the University of Georgia, ... the University of Utah School of Medicine report their findings in ... The ability to acquire iron from their host is an important ...
... 2012) Immune system abnormalities that mimic those seen with ... protein (APP), reports a research team from the University of ... Center. The study, conducted with mouse models of ... in the blood could explain the aberrations in immune cell ...
Cached Biology News:The Encyclopedia of Life expanding at a record pace 2News tips from the journal mBio 2News tips from the journal mBio 3Autism may be linked to abnormal immune system characteristics and novel protein fragment 2